Registration Programme Overview Exhibition Virtual Exhibition Satellite Programme Hotel Information VISA Letter Application

 

Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

5-year results after canaloplasty and the influence of the local glaucoma therapy at baseline to its intraocular pressure lowering efficacy

Poster Details


First Author: S.Fili GERMANY

Co Author(s): I. Vastardis   M. Kohlhaas                 

Abstract Details

Purpose:

To report the outcomes of canaloplasty as glaucoma procedure in eyes with primary open-angle glaucoma concerning the long term efficacy in reducing the IOP and the number of glaucoma eye drops.

Setting:

Clinic of Ophthalmology, St.-Johannes-Hospital in Dortmund, Germany

Methods:

A retrospective study with 602 eyes, in which canaloplasty was indicated for long-term intraocular pressure reduction. Comparison of postoperative results of IOP in the group of eyes that received less than two glaucoma eye drops at baseline and in the of eyes that received more than two glaucoma eye drops at baseline were evaluated. The follow-up time was 5 years.

Results:

The long-term reduction of intraocular pressure was satisfying after 12 months with an average intraocular pressure of 15,6 ± 5,2 mmHg under 0,4 ± 1,0 agents in comparison to 19,6 ± 6,7 mmHg mmHg under 2,6 ± 1,0 agents preoperatively and remain stable at 15,9 ± 5,0 mmHg under 0,5 ± 0,5 agents. (Anova, p<0,05). This refers to 18,9% and 20,4% reduction of the IOP after 12 and 24 months respectively with 80,8% as significant decrease of the number of the eye drops.

Conclusions:

Canaloplasty provides a long-term postoperative hypotensive effect in patients with moderate POAG and a stabilization of the IOP with less glaucoma agents in patients with advanced POAG, that received at baseline a local therapy with more than two glaucoma agents.However, we observed not only a short-term but also a long-term insufficient lowering of the IOP in eyes, that were treated with more than 2 glaucoma agents

Financial Disclosure:

None

Back to Poster listing